RxDoctor Payments Data

Deana McLaughlin

Adult Health · Ravenna, OHNPI 1689693251

Payments from drug & device makers

$1,352in general payments, 2019–2025

Across 57 payments — averaging $23.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$279
  • Novartis$223
  • Impulse Dynamics (USA) Inc.$181
  • Merck$89
  • Scpharmaceuticals Inc.$87
  • Amgen$67
  • plus $427 from 14 others

What the payments were for

  • Food & beverage$1,352100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,352 in reported general payments places this provider in the 75th percentile of 1,184 adult health providers in Ohio.

See all adult health providers in Ohio

Medicare billing

Part B allowed, 2024
$26,100
Medicare patients
157
Services billed
510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan354$481,371
JardianceEmpagliflozin281$334,274
FarxigaDapagliflozin Propanediol232$264,148
EliquisApixaban40$48,856
DapagliflozinDapagliflozin Propanediol12$8,395
Eplerenone76$6,748
Metoprolol Succinate258$4,141
Digoxin34$3,528
Potassium Chloride155$3,307
Carvedilol350$3,176
Spironolactone552$3,132
Bumetanide77$2,970
Torsemide111$2,465
Furosemide581$2,391
Isosorbide Dinitrate38$2,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$223$481,371354 claims
Boehringer IngelheimJardiance$31$334,274281 claims
AstraZenecaFarxiga$57$264,148232 claims
PfizerEliquis$17$48,85640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,184 adult health providers in Ohio.

Other adult health in Ravenna

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →